PROTOCOL NRG-DT001 - Cohort A Reopening to Accrual to Dose Level 2

Cohort A (extremity/body wall) of NRG-DT001, “A Phase IB Trial of Neoadjuvant AMG 232 Concurrent with Preoperative Radiotherapy in Wild-Type p53 Soft Tissue Sarcoma (STS),” is reopened to accrual to dose level 2 effective immediately.

Cohort A will remain open to accrual until 3 wild-type p53 patients have been enrolled to dose level 2. A broadcast with more details regarding accrual closure will be sent when the target accrual has been reached.

Note:Cohort B (abdomen/pelvis/retroperitoneum) is still open to accrual to dose level 1.

Please distribute this information to the appropriate personnel.

This message was sent from NRG-Broadcasts@NRGOncology.org to NRG-Broadcasts@NRGOncology.org
Four Penn Center 1600 JFK Blvd. Suite1020 , Philadelphia, PA, 19103


Update Profile/Email Address | Forward Email | Report Abuse